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Retroviruses by definition insert their viral genome into the host cell chromosome. Although the key player of
retroviral integration is viral integrase, a role for cellular cofactors has been proposed. Lentiviral integrases use the
cellular protein LEDGF/p75 to tether the preintegration complex to the chromosome, although the existence of
alternative host proteins substituting for the function of LEDGF/p75 in integration has been proposed. Truncation
mutants of LEDGF/p75 lacking the chromosome attachment site strongly inhibit HIV replication by competition for the
interaction with integrase. In an attempt to select HIV strains that can overcome the inhibition, we now have used T-
cell lines that stably express a C-terminal fragment of LEDGF/p75. Despite resistance development, the affinity of
integrase for LEDGF/p75 is reduced and replication kinetics in human primary T cells is impaired. Detection of the
integrase mutations A128T and E170G at key positions in the LEDGF/p75–integrase interface provides in vivo evidence
for previously reported crystallographic data. Moreover, the complementary inhibition by LEDGF/p75 knockdown and
mutagenesis at the integrase–LEDGF/p75 interface points to the incapability of HIV to circumvent LEDGF/p75 function
during proviral integration. Altogether, the data provide a striking example of the power of viral molecular evolution.
The results underline the importance of the LEDGF/p75 HIV-1 interplay as target for innovative antiviral therapy.
Moreover, the role of LEDGF/p75 in targeting integration will stimulate research on strategies to direct gene therapy
vectors into safe landing sites.
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Introduction
Although a dynamic interplay between the virus and host
factors occurs at all steps of the HIV replication cycle, the
identity and role of these cellular cofactors are poorly
understood. LEDGF/p75 is a cellular cofactor of HIV-1
integrase (IN), which catalyses integration of the HIV-1
DNA into the host cell genome [1]. LEDGF/p75 was found
to interact with HIV-1 IN following coimmunoprecipitation
of nuclear extracts of cells stably expressing IN from a
synthetic gene [2]. The tight binding between LEDGF/p75 and
IN was corroborated independently [3,4] and found to be
lentivirus speciﬁc [5–7]. The protein of 530 amino acids
contains a PWWP domain at the N terminus that may be
involved in chromatin binding [8,9]. The interaction of
LEDGF/p75 with IN is mediated by a minimal IN-binding
domain (IBD) [10,11], in the C-terminal region of the protein
(amino acids 347 to 429). LEDGF/p75 appears to function as a
tethering factor, linking IN to the chromatin [12,13]. A recent
report suggested a modest contribution of LEDGF/p75 to the
targeting of HIV-1 integration, implying a role for alternative
cofactors [14].
Several studies have addressed the question whether
LEDGF/p75 is an important cofactor for viral replication in
vivo. The Q168 residue in HIV-1 IN was found to be critical
for the interaction with LEDGF/p75 [4]. A virus clone
containing this single point mutation was defective for
replication due to a block at the integration step [4]. Two
studies failed to observe a reduction in HIV-1 replication
after partial knockdown of LEDGF/p75 [6,15]. Vandekerck-
hove et al. [16], however, proved that more potent, transient
or stable knockdown of LEDGF/p75 results in a signiﬁcant
inhibition of HIV-1 replication in different cell lines. These
data have been independently conﬁrmed [17,18]. The most
potent inhibition of HIV-1 replication was observed upon
stable overexpression of C-terminal fragments of LEDGF/p75
fused to the enhanced green ﬂuorescent protein (eGFP).
These fragments compete with LEDGF/p75 for binding to IN.
The absence of chromatin interaction domains renders these
fragments dysfunctional for tethering integration [19].
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In this study, we show that HIV can develop resistance to
overexpressed truncation variants of its own cellular cofac-
tor, although at the expense of a reduced afﬁnity to LEDGF/
p75 and highly reduced replication kinetics. To our knowl-
edge, such resistance phenotype to a cellular cofactor has not
been described before. Detection of mutations at key
positions in the LEDGF/p75–IN interface provides critical
evidence of the importance of LEDGF/p75 for viral repli-
cation.
Results
Selection of HIV-1 Strains Resistant to Inhibition by the
Overexpressed C-Terminal Fragment of LEDGF/p75
Overexpression of LEDGF/p75 truncation mutants con-
taining the IBD severely inhibits viral replication [19]. Figure
S1A represents a hypothetical scheme of HIV-1 integration in
wild-type (WT) MT-4 cells and MT-4 cells overexpressing the
LEDGF/p75 truncation mutant eGFP-D325 (MT-4 eGFP-
D325). The fusion protein eGFP-D325 consists of the C-
terminal fragment of LEDGF/p75 (amino acids 325 to 530)
fused to the C terminus of eGFP. In WT MT-4 cells, the viral
IN associates with LEDGF/p75 and is tethered to the
chromatin, facilitating the integration of the viral cDNA in
the host genome. Upon overexpression of eGFP-D325, the
eGFP-D325 fusion competes with endogenous LEDGF/p75 for
interaction with IN and thereby inhibits viral integration.
Note that it is possible that recruitment of LEDGF/p75 versus
D325 does not take place in the nucleus but may already
occur in the cytoplasm [6]. Figure S1B displays replication of
WT virus in MT-4 eGFP-D325 and MT-4 eGFP-D325 D366A
cells. The control cells overexpress the D366A mutant of
eGFP-D325 known to be defective for interaction with HIV-1
IN [20]. While HIV-1 replication is readily detected in MT-4
eGFP-D325 D366A mutant cell lines, HIV-1 replication is
inhibited more than 20-fold 4 d postinfection in the MT-4
eGFP-D325 cells. The virus breaking through at 9 d post-
infection is not resistant to the inhibitory effect of eGFP-
D325 (unpublished data); limited HIV replication is allowed
in cells where the eGFP-D325 fusion protein is competing for
LEDGF/p75. Moreover, no mutations were detected in the IN
gene of this virus (unpublished data). Therefore, we started to
select resistant strains by repeated passaging of HIV-1 (NL4.3)
in MT-4 eGFP-D325 cells. As a control, virus was passaged in
parallel in MT-4 eGFP-D325 D366A cells. By reducing the
volume of the inoculum (i.e., decreasing the multiplicity of
infection [MOI]), selective pressure was progressively in-
creased during the experiment.
Figure 1 shows the progressive increase in mutation
frequency in the IN coding region while increasing selective
pressure (decreasing MOI). Selection up to 21 passages (#21)
in MT-4 eGFP-D325 cells resulted in a virus population with
100% of the strains containing both the A128T and the
E170G mutation in the IN coding region. No mutations were
identiﬁed in the IN coding region of the control virus
passaged 21 times on the MT-4 eGFP-D325 D366A cells. To
rule out cell type dependence, serial passaging of virus was
also done in HeLaP4 eGFP-IBD Tet/off and HeLa P4 eGFP-
D325 Tet/off cells (unpublished data) [19]. These selection
experiments identiﬁed the mutations A128T, W131G, K156N,
and G163E that mapped to the same regions in the IN gene.
Since MT-4 cells better resemble natural host cells of HIV-1
infection, subsequent experiments focused only on the
speciﬁc IN mutations found by selection in MT-4 eGFP-
D325 cells. After 21 passages (#21), two mutations, V38A and
S113N, were also found in the gp120 encoding regions of the
selected virus population; however, they were present in only
25% and 50% of the virus population, respectively. More-
over, these mutations were also detected in the gp120 gene of
the virus population passaged on MT-4 eGFP-D325 D366A
cells, although in a lower percentage of the virus population.
These mutations likely represent adaptation of the virus to
cell culture and infection conditions.
HIV-1 Overcomes Inhibition by eGFP-D325
Overexpression
To verify whether the selected HIV-1 strains were indeed
less susceptible to the inhibitory effect of the overexpressed
LEDGF/p75 C-terminal domain, MT-4 eGFP-D325 and MT-4
eGFP-D325 D366A cells were infected with the parental HIV-
1 strain (NL4.3), the HIV-1 strain selected for 21 passages on
MT-4 eGFP-D325 cells (NL4.3/MT-4 eGFP-D325 [#21]), and
the HIV-1 strain selected for 21 passages on MT-4 eGFP-D325
Figure 1. Progressive Accumulation of Mutations in the IN of the HIV-1
Strain Passaged in MT-4 eGFP-D325 Cells
DNA extracts from HIV-1 (NL4.3) infected MT-4 eGFP-D325 cells were
made at different passages and a genotypic analysis was performed on
the IN gene of these strains. The progressive accumulation of mutations
in IN is depicted. Amino acid substitution relative to the parental WT HIV-
1 (NL4.3) amino acid sequence is shown.
doi:10.1371/journal.ppat.0030047.g001
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Author Summary
Viruses have a limited genome and therefore exploit the cellular
machinery of infected host cells to complete the replication cycle.
Today there is a growing interest to unravel these virus–host
interactions. Lentiviral integrases use the cellular protein LEDGF/p75
to tether the preintegration complex to the chromosome, although
the existence of alternative host proteins substituting for the
function of LEDGF/p75 has been proposed. Here, we used virus
evolution to investigate the role and importance of LEDGF/p75 in
HIV integration and replication. We selected a virus that is resistant
against overexpression of the integrase binding domain of LEDGF/
p75. This virus displays a reduced affinity for its own cofactor but still
depends on the cofactor for replication. We demonstrate the unique
and essential role of LEDGF/p75 in HIV replication and support the
LEDGF/p75 HIV-1 interplay as target for innovative antiviral therapy.
Moreover, elucidation of the role of LEDGF/p75 in targeting
integration will stimulate research on strategies to direct gene
therapy vectors into safe landing sites.
D366A cells (NL4.3/MT-4 eGFP-D325 D366A [#21]) [19]
(Figure 2A and 2B). HIV-1 infection was done at an MOI of
0.1, and the different viral strains were normalized on p24
content. HIV-1 replication was readily detected in control
cells overexpressing eGFP (MT-4 eGFP) (Figure 2D) and MT-4
eGFP-D325 D366A cells (Figure 2B) for all strains used. As
previously shown, no WT viral replication could be detected
in MT-4 eGFP D325 cells until 96 h postinfection (Figure 2A)
[19]. Similar results were obtained for the control virus
passaged on MT-4 eGFP-D325 D366A cells (NL4.3/MT-4
eGFP-D325 D366A [#21]). On the contrary, for the HIV-1
strain selected for 21 passages on MT-4 eGFP-D325 cells
(NL4.3/MT-4 eGFP-D325 [#21]), viral replication in MT-4
eGFP-D325 cells was evident from the onset of infection.
Identical results were obtained in MT-4 eGFP-IBD cells
overexpressing a fusion protein of eGFP to the IBD of
LEDGF/p75 [19] (Figure 2C).
Both A128T and E170G IN Mutations Are Necessary and
Together Sufficient for Viral Rescue
To evaluate the importance of the described mutations for
the observed resistant phenotype, these mutations were
cloned in the HIV-1 NL4.3 molecular clone (pNL4.3) as
single or double mutants (pNL4.3 A128T, pNL4.3 E170G, and
pNL4.3 A128T/E170G, respectively). Susceptibility of the
molecular clones to eGFP-D325 overexpression was deter-
mined by studying multiple round HIV-1 replications in MT-
4 eGFP-D325 (Figure 3A) and in MT-4 eGFP-D325 D366A cells
(Figure 3B). The experiments were carried out at an MOI of
0.5, and the different viral strains were normalized on p24
content. HIV-1 replication was clearly detected in MT-4
eGFP-D325 D366A cells for all strains used, although all
mutated strains showed a reduced replication capacity
compared with WT NL4.3. Whereas the double mutant
NL4.3 A128T/E170G rescued HIV-1 replication in MT-4
eGFP-D325 cells, the single mutants NL4.3 A128T and
NL4.3 E170G could only partially restore viral replication.
Apparently, both IN mutations are necessary and together
sufﬁcient for the strong rescue phenotype of the selected
HIV-1 strain in MT-4 eGFP-D325 cells.
Resistance to eGFP-D325 Overexpression Is Accompanied
by Reduced Viral Replication Kinetics and Reduced
Enzymatic Activity of IN
The mutations detected in the IN gene have not been
described before. Therefore, we studied the impact of the IN
Figure 2. An HIV-1 Strain Is Selected to Replicate in eGFP-D325 Overexpression Cells
The MT-4 cell lines were infected at an MOI of 0.1 with the following viral strains: WT NL4.3 (filled diamonds), HIV-1 (NL4.3) (crosses) selected for 21
passages in MT-4 eGFP-D325 cells (NL4.3/MT-4 eGFP-D325 [#21]), and HIV-1 (NL4.3) (open diamonds) selected for 21 passages in MT-4 eGFP-D325
D366A cells (NL4.3/MT-4 eGFP-D325 D366A [#21]). The viral strains were normalized on p24 content and viral replication was followed by daily
measurement of p24 concentration in the supernatant. (A) MT-4 eGFP-D325, (B) MT-4 eGFP-D325 D366A, (C) MT-4 eGFP-IBD, and (D) MT-4 eGFP cells. All
experiments were performed in duplicate. Average 6 SD values are shown.
doi:10.1371/journal.ppat.0030047.g002
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mutations on the enzymatic level in an oligonucleotide-based
overall integration assay (Figure 4A). All mutants were
enzymatically active, albeit to a lower extent than IN-WT.
The IN-A128T enzyme displayed a 3-fold reduction in overall
enzymatic activity. The IN-E170G and the IN-A128T/E170G
IN mutants both displayed a 2-fold reduction in overall
enzymatic activity compared with IN-WT.
To investigate whether the selected IN mutations affect the
viral replication kinetics, the mutant molecular clones were
examined for their ability to replicate in peripheral blood
lymphocytes (PBLs) (Figure 4B). All mutants showed substan-
tially reduced replication ﬁtness in comparison with WT
NL4.3 (Figure 4B). Replication kinetics of the double mutant
NL4.3 A128T/E170G and the single mutant NL4.3 E170G were
decreased 4-fold relative to the replication of WT NL4.3 as
evaluated by p24 measurements. The NL4.3 A128T strain
showed a 2-fold difference in replication capacity.
Virus Resistant to eGFP-D325 Overexpression Displays
Reduced 2-LTR Circle Formation and Integration
To determine the step at which the replication cycle of
eGFP-D325 resistant virus is affected, real-time quantitative
PCR analysis was performed to quantify the formation of the
different DNA species in the cell. To ensure single-round
infection, 293T cell lines were infected with vesicular
stomatitis virus G protein (VSV-G) pseudotyped virus. DNA
was extracted at several time points postinfection. As shown
in Figure S2A, none of the mutants affected the accumulation
of viral DNA at early time points. On the other hand, the
number of 2-LTR circles decreased 4-fold for the NL4.3
A128T, NL4.3 E170G, and NL4.3 A128T/E170G virus com-
pared with WT NL4.3 (Figure S2B). The 2-LTR circles are
formed in the nucleus and are an indirect indication for
nuclear import of the preintegration complex (PIC). Finally,
the integration events in 293T cells were measured by real-
time Q-Alu PCR. A 3- to 4-fold reduction in the number of
proviruses was revealed for all HIV mutants (Figure S2C).
To analyze the rescue of viral replication by real-time
quantitative PCR, 293T eGFP-D325 cells and control 293T
eGFP-D325 D366A cells were infected with WT VSV NL4.3 or
VSV NL4.3 A128T/E170G. As shown in Figure S2D, the
accumulation of viral DNA at early time points was not
affected upon expression of eGFP-D325. As was previously
stated for WT virus, the number of 2-LTR circles increased
more than 10-fold in the 293T eGFP-D325 cells [19] (Figure
S2E). However, this increase was signiﬁcantly lower when the
cells were infected with NL4.3 A128T/E170G virus. Integra-
tion could not be measured by real-time Q-Alu PCR, which
makes use of an LTR primer that anneals to the lentiviral
vector sequences used to make these cell lines. Therefore,
infected cells were passaged at least four times (six cell
divisions) to dilute nonintegrated DNA, ensuring that only
integrated copies of viral DNA remained. The absence of 2-
LTR circles at 48 h postinfection (Figure S2E) is an
experimental proof for the loss of nonintegrated DNA.
Measuring total HIV-1 DNA after four passages pointed to
a rescue in the number of proviruses in the 293T eGFP-D325
for the NL4.3 A128T/E170G virus in comparison with WT
virus (Figure S2F).
Confocal Imaging Suggests a Decreased Affinity of mRFP-
A128T/E170G-INs for eGFP-D325 and LEDGF/p75
Apparently, we selected a virus that can overcome a
replication block by a fragment of an essential cofactor, by
altering the interaction between IN and the fragment.
Experiments were designed to directly demonstrate that the
IN mutations affect the interaction with (the C-terminal
fragment of) LEDGF/p75. First, confocal imaging was used to
study the cellular localization of the different mutant INs
(Figure S3A). As expected, due to its interaction with
endogenous LEDGF/p75, a transiently expressed monomeric
red ﬂuorescent protein-WT-INs (mRFP-INs) fusion protein
localized to the nucleus of WT HeLaP4 cells (Figure S3A) [21–
26]. Identical results were obtained for mRFP-A128T-INs.
However, mRFP-E170G-INs and mRFP-A128T/E170G-INs
were more dispersed throughout the cell, although some
residual nuclear localization could be observed. This suggests
a reduced afﬁnity of the mRFP-A128T/E170G-INs for LEDGF/
p75. Indeed, upon overexpression of eGFP-LEDGF/p75, a
remarkable relocalization of the mutant A128T/E170G IN to
the nucleus was observed (Figure S3C), which suggests that
high levels of LEDGF/p75 can overcome the loss in afﬁnity. As
Figure 3. Susceptibility of Mutant Viral Clones to eGFP-D325 Overexpression
Viral clones that contain either one or both selected mutations were engineered. MT-4 eGFP-D325 (A) and MT-4 eGFP-D325 D366A cells (B) were
infected at an MOI of 0.5 with the following viral clones: WT NL4.3 (diamonds), NL4.3 A128T (boxes), NL4.3 E170G (triangles), or NL4.3 A128T/E170G
(crosses). The different viral clones were normalized on p24 content and viral replication was followed by daily measurement of p24 concentration in
the supernatant. All experiments were performed in duplicate. Average 6 SD values are shown.
doi:10.1371/journal.ppat.0030047.g003
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previously described, an explicit cytoplasmic relocalization of
both the WT mRFP-INs fusion protein and eGFP-D325 is
observed in HeLaP4 eGFP-D325 cells (Figure S3B) [19].
Similar results were obtained with mRFP-A128T-INs. But
upon overexpression of E170G-INs or mRFP-A128T/E170G-
INs in HeLaP4 eGFP-D325 cells, cytoplasmic relocalisation
was less explicit. In the control HeLaP4 eGFP-D325 D366A
cells, expressing interaction-defective eGFP-D325 (Figure
S3B), the A128T/E170G fusion protein was also present
throughout the cell, reﬂecting the loss of interaction. These
data suggest a reduced afﬁnity of mRFP-A128T/E170G-INs for
the eGFP-D325 fusion protein.
Characterization of the Interaction between the Mutant
INs and LEDGF/p75 or eGFP-D325
Confocal imaging suggests a decreased afﬁnity of mRFP-
A128T/E170G-IN for eGFP-D325 and LEDGF/p75. To further
characterize these interactions, we investigated the ability of
the mutant INs to interact with LEDGF/p75, MBP-IBD, and
MBP-D325 using an in vitro pull-down assay (Figure 5A). Both
C-terminal His-tagged WT INs (IN-WT) and IN containing the
A128T mutation (IN-A128T) were able to pull down LEDGF/
p75, MBP-IBD, and MBP-D325. On the contrary, almost no
interaction was detected with the E170G or A128T/E170G
double mutation. The same results were obtained when N-
terminal WT and mutant His-tagged INs for pull-down were
used (unpublished data). The highly reduced interaction of
MBP-D325 with IN-E170G and IN-A128T/E170G was analyzed
in more detail with different IN and MBP-D325 concen-
trations using AlphaScreen technology (Figure 5B). In this
assay, C-terminal His6-tagged IN was added to different
concentrations of MBP-D325. Ni-chelate–coated acceptor
beads and anti-MBP–coated donor beads were added to bind
IN or MBP-D325, respectively. Binding of the molecules to the
beads results in an energy transfer from one bead to the
other, producing a ﬂuorescent signal. Representative inter-
Figure 4. Effect of the IN Mutations on Enzymatic Activity and Replication Kinetics
(A) Activities of recombinant IN were tested in an oligonucleotide-based assay. Activity of a 2-fold dilution series of each enzyme was determined,
starting at a concentration of 2 lM. Reaction products were separated in a denaturating urea gel and visualized with a PhosphorImager. The enzymatic
activity was determined by measuring strand transfer products for the single mutants IN-A128T and IN-E170G and the double mutant IN-A128T/E170G
in comparison with WT-IN. Unprocessed substrate was run as a control (lane 1: NC).
(B) PBLs were inoculated with WT or mutant viral clones at an MOI of 0.01: WT NL4.3 (diamonds), NL4.3 A128T (boxes), NL4.3 E170G (triangles), or NL4.3
A128T/E170G (crosses). Culture supernatants were collected daily and p24 antigen production was monitored. Experiments were done in duplicate.
Average 6 SD values are shown.
doi:10.1371/journal.ppat.0030047.g004
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action spectra are shown in Figure 5B. Background ﬂuo-
rescence was subtracted from the ﬂuorescence signal of the
samples. At an IN concentration of 30 nM, the ﬂuorescent
signal of the IN-WT and IN-A128T enzymes increased upon
increasing MBP-D325 concentrations (from 30 to 300 nM)
until a plateau was reached. No ﬂuorescent signal above
background could be detected for the IN-E170G and the IN-
A128T/E170G mutants. When a higher amount of IN (300 nM)
was incubated with increasing MBP-D325 concentrations
(from 30 to 300 nM), ﬂuorescent signal could also be detected
for the IN-E170G and the IN-A128T/E170G mutants. Still,
interaction of IN-A128T/E170G to MBP-D325 (300 nM) was
reduced 8-fold compared with IN-WT. Binding of IN-A128T
and IN-E170G to MBP-D325 was reduced 2-fold and 3-fold,
respectively. These results clearly indicate that the afﬁnity of
the double mutant IN-A128T/E170G to MBP-D325 is highly
reduced. However, at high concentrations of both proteins, in
vitro binding remains possible.
To further characterize these interactions in vivo, we
applied ﬂuorescence cross-correlation spectroscopy (FCCS)
in HeLa-P4 derived cell lines. This method allows the
quantiﬁcation of the interaction of two ﬂuorescently labeled
proteins in cellulo by measuring simultaneous diffusion.
Because the diffusion of the complex mRFP-INs and eGFP-
LEDGF/p75 is strongly reduced in the nucleus—most prob-
ably due to interactions with chromatin—we could not
quantify interactions in the nucleus. Therefore, the K150A
NLS mutation was introduced in LEDGF/p75 to overcome the
nuclear localization [27], and measurements were done in the
cytoplasm of the cell. HeLaP4 eGFP-D325 or HeLaP4 cells
overexpressing eGFP-LEDGF/p75(K150A) were transfected
with plasmids encoding WT or double mutant mRFP-INs. As
Figure 5. Resistance to eGFP-D325 Overexpression Is Accompanied by Reduced In Vitro Binding to LEDGF/p75
(A) His6-tag IN mediated pull-down of LEDGF/p75, MBP-IBD, and MBP-D325. Recombinant LEDGF/p75, MBP-IBD, or MBP-D325 was incubated with His6-
tagged HIV-1 IN, and complexes were recovered using Ni2þ-NTA beads. Proteins were separated via a 12.5% SDS-PAGE gel and detected using
Coomassie Blue staining. Molecular weight markers are indicated on the left side of each gel. Pull-down controls, which represent pull-downs of single
proteins, are shown in the left gel, next to the input of each protein. The right gel displays the recovered proteins after pull-down.
(B) Interactions between His6-tagged IN and MBP-D325 were determined using AlphaScreen technology. Two different concentrations of IN (30 nM or
300 nM) were incubated with various amounts of MBP-D325. As a negative control, 300 nM MBP-D325 was incubated without IN. Ni-chelate–coated
acceptor beads and anti-MBP–coated donor beads were added to bind IN or MBP-D325, respectively. IN-MBP-D325 interaction was measured with the
AlphaScreen method. Experiments were performed twice. A representative experiment is shown.
doi:10.1371/journal.ppat.0030047.g005
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a negative control, cells were transfected with an mRFP
expression plasmid. Compared to the negative control, cross-
correlation of eGFP-D325 or eGFP-LEDGF/p75(K150A) with
WT mRFP-INs was readily detected (p , 0.01), indicating that
both proteins interact with WT IN in the cytoplasm of the
living cell (Figure 6). The binding of WT and double mutant
IN to eGFP-D325 was compared as well as the interaction of
WT and double mutant IN with eGFP-LEDGF/p75. The
mutations affected both interactions signiﬁcantly (p ,
0.001). The cross-correlation signal for the interaction of
A128T/E170G mRFP-INs with eGFP-D325 was more affected
than that for interaction with full-length LEDGF/p75,
suggesting that the mutations in viral IN differentiate
between D325 and full-length LEDGF/p75.
A crystal structure of the dimeric catalytic core domain
(CCD) of HIV-1 IN complexed to the IBD of LEDGF/p75 was
previously reported [28]. A128 is part of the a3 helix in the
IN-CCD, which forms a hydrophobic patch that accommo-
dates the side chains of the LEDGF/p75 residues I365, F406,
and V408 [28]. E170 is part of the so-called a4/5 connector, a
six-residue connector linking helices a4 and a5 of the second
IN chain (residues 166 through 171). These two regions were
reported to be the main structural features of IN recognized
by LEDGF/p75. Biomolecular modeling was performed to
predict the inﬂuence of the IN mutations on the interaction
of IN and LEDGF/p75 (Figure S4A and S4B). Substituting
alanine for threonine at position 128, and performing a
structure energy minimization, resulted in a slightly de-
creased binding afﬁnity of IN for IBD, with an increase in
binding energy from 68.02 to 61.03 kcal/mol. Apparently,
the bulky side chain of threonine causes sterical hindrance,
thereby forcing the I368 residue of the IBD to adapt a
different conformation. This occurs without a drastic
inﬂuence on the conformation of residues in the LEDGF/
p75–IN binding interface. Substituting glutamic acid for
glycine at position 170 has a more drastic effect. This
mutation results in a different conformation of the loop
disrupting two interactions. First, the double hydrogen bond
between the hydrogens of the loop backbone at residues E170
and H171 and D366, a critical interacting residue on LEDGF/
p75, is broken. Second, the electrostatic interaction of E170
(IN) with K364 (LEDGF/p75) is abolished. These effects cause
a signiﬁcant decrease in binding afﬁnity, with an increase in
predicted binding energy from 68.02 to 56.38 kcal/mol.
When both IN mutations are present, the overall binding
energy for the IBD–IN complex is increased from 68.02 to
53.10 kcal/mol.
Virus Resistant to eGFP-D325 Overexpression Is
Dependent on LEDGF/p75 for Replication
How does HIV overcome the replication block induced by
the C-terminal fragment of its cofactor? FCCS measurements
suggest that by altering the afﬁnity of IN for the cofactor,
HIV-1 may be capable to discriminate between endogenous
LEDGF/p75 and the inhibiting C-terminal fragment (eGFP-
D325). Alternatively, HIV-1 that has become deﬁcient for
interaction with LEDGF/p75 may replicate independently
from LEDGF/p75, by employing another cofactor. The latter
explanation has been put forward recently after analysis of
integration sites in LEDGF/p75 knockdown cells [14]. LEDGF/
p75 knockdown only resulted in a modest shift in integration
site selection. To address this question, replication of the
virus resistant to eGFP-D325 overexpression was followed in
LEDGF/p75 knockdown cells. Stable polyclonal MT-4 LEDGF/
p75 knockdown cells were generated using lentiviral vectors
encoding shRNA targeting LEDGF/p75 (MT-4 p75). As a
control, four mutations were introduced in the short hairpin
against LEDGF/p75, and MT-4 cells were generated (MT-4
mut). Efﬁciency of knockdown was veriﬁed by Western
blotting (Figure 7A). Infection of these cell lines with WT
NL4.3 at an MOI of 0.5 resulted in a 5- to 10-fold reduction in
viral replication as measured by p24 antigen production in
the supernatant (Figure 7B). In the control cells encoding the
mutant hairpin (MT-4 mut), no reduction of HIV-1 repli-
cation was observed. No breakthrough of the mutant NL4.3
A128T/E170G virus was detected up to 10 d postinfection in
MT-4 p75 cells (MOI 0.5) (Figure 7B). Moreover, viral
replication of the NL4.3 A128T/E170G virus was inhibited
10-fold more than that of WT virus in MT-4 p75 cells. In the
control MT-4 mut cells, both strains showed equivalent viral
replication. The inhibitory effect on the WT virus in the MT-
4 p75 cells could be overcome by using a higher MOI (MOI
2.5) (Figure 7C). However, at the same MOI, NL4.3 A128T/
E170G replication remained 10-fold lower. The same experi-
ment was performed in the LEDGF/p75 knockdown Jurkat
cells p75() Cl 2 (Jurkat p75) and p75() Cl 2 back-
complemented (BC) (Jurkat BC) cells that were originally
Figure 6. In Vivo Interaction of WT and Mutant HIV-1 IN with LEDGF/p75
and eGFP-D325
HeLaP4 eGFP-D325 or HeLaP4 cells overexpressing eGFP-LEDGF/
p75(K150A) in the cytoplasm were transfected with plasmids encoding
WT or double mutant A128T/E170G mRFP-INs. As a negative control, cells
were transfected with an mRFP expression plasmid. Interaction between
eGFP-D325 or eGFP-LEDGF/p75(K150A) with WT mRFP-INs or A128T/
E170G mRFP-INs was detected by measuring the simultaneous diffusion
of the differentially labeled proteins using FCCS. The interaction is
presented as the relative extent of cross-correlation (data are shown in
box plots with SD for 30 measurements). A two-sample t-test was
performed to prove that the different samples were drawn from different
populations. The two samples are statistically different if p , 0.01. Since
cross-correlation is concentration dependent, WT IN was compared with
double mutant IN for binding to eGFP-D325 and for binding to eGFP-
LEDGF/p75. The respective reduction in affinity is represented by the
arrow, and the accompanying p-values are shown at the top of the
figure.
doi:10.1371/journal.ppat.0030047.g006
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reported by Llano et al. [6]. Llano and coworkers did not
detect any reduction in viral replication in these knockdown
cells compared with the BC control cells. In agreement, we
could not detect any inhibition of replication of WT NL4.3 in
these cells (Figure 7D). However, replication levels of A128T/
E170G virus were 10-fold lower in the Jurkat p75 cells,
whereas no signiﬁcant reduction of HIV-1 replication was
observed in the BC Jurkat cells for any of the strains used. We
reason that replication of the mutant virus should not be
inhibited in cells with highly reduced levels of LEDGF/p75, if
this replication occurs independently of LEDGF/p75. To the
contrary, our experiments suggest that the virus resistant to
eGFP-D325 overexpression has a reduced afﬁnity for LEDGF/
p75, making it more vulnerable to reduction of LEDGF/p75
levels. It is clear that LEDGF/p75 is still employed by the virus
for viral replication in eGFP-D325 overexpressing cells. Our
data are thus at odds with the existence of another cofactor
that can substitute for LEDGF/p75.
In line with these results and to further strengthen our
model that the A128T/E170 virus is still capable of interacting
with LEDGF/p75 in vivo, we speculated that poor replication
of the double mutant virus in WT cells could be rescued by
overexpression of LEDGF/p75. For this purpose, MT-4 cells
stably overexpressing LEDGF/p75 and MT-4 cells stably
overexpressing eGFP were generated. Overexpression was
veriﬁed by Western blot analysis (Figure S5A). These cell lines
were used to compare replication of WT NL4.3 virus and
A128T/E170G NL4.3 virus (Figure S5B). In the control MT-4
eGFP cells, replication kinetics of the double mutant NL4.3
A128T/E170G was decreased 2-fold in comparison to the WT
HIV-1 NL4.3. However, in MT-4 cells overexpressing LEDGF/
p75, replication of both virus strains was similar. This
experiment again suggests that poor replication of the IN
mutants in WT cells is due to reduced afﬁnity for LEDGF/p75
and that the A128T/E170 IN mutant virus still exploits
LEDGF/p75 in vivo.
Discussion
We have previously characterized LEDGF/p75 mutants
containing the IBD but lacking the chromosome attachment
site (eGFP-D325 and eGFP-IBD) that strongly impair HIV-1
replication by competing for the interaction with IN [19]. We
have now selected HIV-1 strains resistant to such a truncation
mutant of LEDGF/p75 (eGFP-D325) (Figure 2). Two mutations
were detected in the IN coding region at key positions in the
LEDGF/p75–IN interface (A128T and E170G) (Figure 1). This
corroborates that the speciﬁcity of the observed inhibition in
viral replication in MT-4 eGFP-D325 cells is unambiguously
based on the direct interaction of the overexpressed D325
fragments with IN. The available crystallographic data on the
IN-IBD interface [28] were recently questioned after an in
vitro mutagenesis study that failed to observe a strict
correlation between the interaction of IN with LEDGF/p75
Figure 7. Virus Resistant to eGFP-D325 Overexpression Is Dependent on LEDGF/p75 for Replication
(A) Western blot analysis of LEDGF/p75 expression levels in MT-4 cells (lane 1) and stable MT-4 knockdown cell lines (MT-4 p75) (lane 3). As a control,
MT-4 cells expressing a mismatch shRNA against LEDGF/p75 were made (MT-4 mut) (lane 2). Equal loading of gels was controlled by a-tubulin
detection.
(B and C) MT-4 p75 and MT-4 mut cells were infected at an MOI of 0.5 (B) or 2.5 (C) with the following viral clones: WT NL4.3 (diamonds) or NL4.3
A128T/E170G (crosses).
(D) Jurkat cells encoding a shRNA directed against LEDGF/p75 (Jurkat p75 cells) and BC Jurkat cells were infected at an MOI of 0.5 with WT NL4.3
(diamonds) or NL4.3 A128T/E170G (crosses). The different viral strains were normalized on p24 content, and viral replication was followed by daily
harvesting of the supernatant and measurement of p24 concentration. Experiments were run in duplicate. Average 6 SD values are shown.
doi:10.1371/journal.ppat.0030047.g007
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and the effect on HIV-1 replication [29]. Detection of the IN
mutations A128T and E170G at key positions after resistance
selection provides in vivo conﬁrmation for the previously
reported structure. As biomolecular modelling suggests,
mutating these residues compromises the local structure of
the IBDIN CCD interface, affecting the interaction with
LEDGF/p75 truncation mutants (Figure S4). Our data provide
a striking example of the power of viral molecular evolution.
Not only is the approach apparently more relevant than in
vitro mutagenesis, a virus appears to discriminate between a
fragment of a critical cofactor and the full-length cofactor
itself.
To overcome inhibition by D325, mutations in the IN–IBD
interface are selected. These mutations cripple the virus
considerably (Figure 4). It has been demonstrated before that
mutations associated with antiviral resistance to diketo acids
reduce the enzymatic activity of IN [30,31]. The conservation
of the IN gene compared with other viral genes [32] suggests a
tight restriction in amino acid ﬂexibility. Still, our results
show that viral replication is more affected than enzymatic
activity. The most plausible explanation for the observed
phenotype is that by altering the afﬁnity for the inhibiting C-
terminal fragment, interaction with the critical cofactor
LEDGF/p75 is also jeopardized. Indeed, poor replication of
the double mutant virus in WT cells could be rescued by
overexpression of LEDGF/p75 (Figure S5B). Although HIV
strains have been selected to grow independently of
restriction factors [33,34], this is to our knowledge the ﬁrst
example of selection of a virus that is partially defective for
binding to its cellular cofactor. Although humans carrying a
32–base pair deletion of the CCR5 gene are resistant to HIV-1
infection, no R5 virus has yet been isolated that overcomes
this inhibitory effect; infection is only possible via T-tropic
virus that uses the CXCR4 coreceptor [35].
The reduced replication kinetics of the mutated virus were
further analyzed by quantitative PCR analysis of 293T cells
infected with VSV-G pseudotyped A128T/E170G virus. We
detected a 4-fold decrease in the number of 2-LTR circles and
in integrated provirus (Figure S2). In previous experiments in
which integration was impaired due to partial depletion of
LEDGF/p75 [16,17] or to the presence of competing C-
terminal fragments [19], the amount of 2-LTR circles was
either constant or increased. The reduction in 2-LTR circles
might indicate that the mutations in IN affect nuclear import
of the PIC or the formation of 2-LTR circles. We cannot
exclude that reduced interaction with LEDGF/p75 is respon-
sible for this phenotype. Our previous ﬁnding that LEDGF/
p75 drastically increases the afﬁnity of lentiviral IN for DNA
may imply a role of LEDGF/p75 in the formation of the
complex between IN and the viral DNA. This is the ﬁrst
experimental evidence suggesting that IN-LEDGF/p75 inter-
action might affect steps other than chromosomal tethering/
targeting. The documented presence of LEDGF/p75 in the
cytoplasmatic PIC is consistent with this concept [6].
Analysis of DNA formation by the mutant virus in eGFP-
D325 overexpressing 293T cells revealed that integration of
the resistant virus in the 293T eGFP-D325 cells was restored
(Figure S2F). Whereas the number of 2-LTR circles produced
by WT virus increased more than 10-fold in the 293T eGFP-
D325 cells (Figure S2E) as a result of the defect in integration
(Figure S2F) [19], the number of 2-LTR circles returned to
almost normal levels when the cells were infected with A128T/
E170G virus. These data conﬁrm that the C-terminal frag-
ments speciﬁcally block the integration and/or targeting step.
What is the mechanism underlying the resistant phenotype
observed? Our in vitro data (Figure 5) and in vivo confocal
microscopy analysis (Figure S3) both reveal experimentally
that the mutations that reduce interaction with eGFP-D325
also decrease interaction with full-length LEDGF/p75. The
available structural data support this result. The fact that
A128T/E170G IN displays a reduced afﬁnity for full-length
LEDGF/p75 seems to suggest at ﬁrst sight that HIV can
replicate without LEDGF/p75 perhaps using an alternative
cofactor. In fact, because of the subtle alterations in target
site selection after LEDGF/p75 depletion, the existence of
such a secondary targeting cofactor has been proposed [14].
However, replication of the resistant virus in LEDGF/p75
knockdown MT-4 cells was inhibited 10-fold more than that
of WT virus (Figure 7B). Moreover, replication of A128T/
E170G virus was also severely impaired in the Jurkat p75
cells, which support normal replication of WT virus [6]
(Figure 7D). It follows that LEDGF/p75 is still employed by the
resistant virus that is capable to grow in eGFP-D325
overexpression cells. In fact, poor replication of the double
mutant virus in WT cells is rescued by overexpression of
LEDGF/p75 (Figure S5B), corroborating that the A128T/E170
IN mutant virus still exploits LEDGF/p75 in vivo. Although we
cannot formally exclude the remote possibility that both
mutations also affect binding of the alternative cofactor, its
existence has become unlikely. Reduction of the afﬁnity of IN
for LEDGF/p75 results in a clear phenotype even in cells with
partial depletion of LEDGF/p75. Hence, the failure by Llano
et al. [6] to detect a replication deﬁcit in Jurkat p75 is due to
an insufﬁcient knockdown, as proposed [1,16]. Apparently,
reduced interaction with LEDGF/p75 is preferred rather than
ineffective targeting to the chromatin in the absence of
LEDGF/p75.
Replication of A128T/E170G virus in MT-4 cells over-
expressing LEDGF/p75 truncation mutants suggests that its
afﬁnity for eGFP-D325 is more reduced than for LEDGF/p75,
taking into account that eGFP-D325 is in excess of LEDGF/
p75 (unpublished data). Differential impact of the A128T/
E170G mutation on interaction of recombinant IN with full-
length LEDGF/p75 or the C-terminal fragment could not be
documented in vitro by pull-down (Figure 5A) or Al-
phaScreen technology (unpublished data). Probably, these
assays do not reﬂect the in vivo situation. In vivo FCCS
experiments, however, revealed that mutant IN has a differ-
ent afﬁnity for the cofactor and the inhibiting C-terminal
fragment (Figure 6). Domains in LEDGF/p75 other than the
C-terminus may contribute to the interaction with IN.
Alternatively, the fusion of D325 to eGFP may also aid
A128T/E170G IN to preferentially bind to LEDGF/p75.
The importance of LEDGF/p75 for HIV replication has
been demonstrated over time using mutagenesis [4], RNA
interference [16,17], or overexpression of truncation mutants
[19]. However, none of these experiments could exclude the
existence of other cofactors capable of tethering the PIC to
the chromosomes. Our data indicate that HIV is incapable to
circumvent the LEDGF/p75 function during integration. Our
approach may prove valuable in validating other cellular
cofactors of virus replication. Demonstration of the bio-
logical relevance of the available LEDGF/p75–IN interface,
the impaired replication kinetics upon resistance selection to
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an interaction inhibitor, and the exclusive role in HIV
integration all support the attraction of LEDGF/p75 as an
antiviral target.
Materials and Methods
Plasmids and viral vectors. The construction of the lentiviral
vector transfer plasmids encoding shRNA targeting LEDGF/p75 was
described previously (unpublished data). The construct pmRFP-INs
was used for overexpression of mRFP-INs in HeLaP4 cells [19], and
the construct peGFP-p75 was used to overexpress eGFP-tagged
human LEDGF/p75 in HeLaP4 cells [12]. For bacterial expression of
nontagged LEDGF/p75, C-terminal His6-tagged HIV-1 IN and N-
terminal His6-tagged HIV-1 IN, the plasmids pCPnat75 [12], pKB-
IN6H [12], and pRP1012 [36] were used, respectively. To generate the
A128T or E170G single mutants and double mutants, site-directed
mutagenesis was performed using the Kirsch and Joly method [37].
The presence of the expected mutations was conﬁrmed by DNA
sequencing of the entire IN coding region to ensure no other
mutations were present in the molecular clone. To construct the
lentiviral transfer plasmids pCombi_LEDGF_IRES_Puro, eGFP
was removed from the plasmid pCombi_eGFP_IRES_Puro [19] by
BamHI-SpeI digestion and replaced by BamHI-LEDGF-XbaI. This
fragment was obtained by PCR ampliﬁcation using the primers
LEDGF-forw (59-GGC GGG ATC CAG ACA CCA TGA CTC GCG
ATT TCA AAC C-39) and LEDGF-rev (59-CAG GTC TAG ACT AGT
TAT CTA GTG TAG AAT CCT TC-39) using pEF1-LEDGF-Back [6] as
a template. Subsequently, the resulting products were digested with
BamHI and SpeI. Production of lentiviral vectors was performed as
described previously by Geraerts et al. [38].
Cells. MT-4 cells [39], 293T cells, HeLaP4 cells, Jurkat cells, and
PBLs were grown in a humidiﬁed atmosphere with 5% CO2 at 37 8C.
The 293T cells were obtained from O. Danos (Ge´nethon, Evry,
France) and grown in DMEM (GIBCO BRL, Merelbeke, Belgium,
http://www.invitrogen.com) supplemented with 10% heat-inactivated
fetal calf serum (FCS; Harlan Sera-Lab, http://www.harlaneurope.
com), 2 mM glutamine (GIBCO BRL), 100 U/ml penicillin (GIBCO
BRL), and 100 lg/ml streptomycin (GIBCO BRL). HeLaP4 cells,
obtained from the National Institutes of Health Reagent program,
were grown in DMEM containing 10% FCS, 100 lg/ml streptomycin,
100 U/ml penicillin, and 0.5 mg/ml geneticin (GIBCO BRL). MT-4 cells
and Jurkat cells were maintained in RPMI 1640 (GIBCO BRL)
supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine,
0.1% sodium bicarbonate (GIBCO BRL), 100 U/ml penicillin, and 100
lg/ml streptomycin. Medium for maintenance of Jurkat cells addi-
tionally contained 0.1% sodium pyruvate (100 mM) (GIBCO BRL).
Peripheral blood was obtained by venipuncture from HIV-sero-
negative healthy donors. PBLs were isolated by centrifugation on
gradient medium (Lymphoprep; Axis-Shield, Oslo, Norway), washed
twice in PBS, and resuspended in RPMI 1640. PBLs were maintained
in RPMI 1640 supplemented with 15% heat-inactivated FCS, 2 mM L-
glutamine, 0.1% sodium bicarbonate, and 0.5 mg/ml gentamycin
(GIBCO BRL). Cells were stimulated 3 d prior to use with 5 U/ml
in t e r l euk in - 2 (Roche App l i ed S c i enc e , h t t p : / / www .
roche-applied-science.com) and 2 lg/ml phytohemagglutinin (PHA)
(Sigma-Aldrich, http://www.sigmaaldrich.com). During experiments,
PBL medium contained 10 U/ml interleukin-2. Generation and
selection of MT-4 eGFP-D325, MT-4 eGFP-D325 D366A, MT-4
eGFP-IBD, MT-4 eGFP, and its HeLa P4 and 293T equivalents were
described previously [19]. Jurkat cells p75() Cl 2 and Jurkat cells
p75()Cl 2 BC were obtained from E. M. Poeschla (Rochester,
Minnesota, United States) [13]. Generation and selection of stable
MT-4 LEDGF/p75 knockdown cells were done using lentiviral vector
transfer plasmids encoding an shRNA targeting LEDGF/p75 driven by
an mU6 promotor and a CMV-driven eGFP-ZEOCIN fusion gene
(unpublished data). MT-4 cells (13 105 ) were transduced at an MOI
of 1 and selected with 200 lg/ml zeocin (Invitrogen). Finally, the 10%
of the highest MT-4shp75 eGFP expressor cells were sorted, until a
total of 105 cells was reached, using the FACSVantage (BD
Biosciences, http://www.bdbiosciences.com) [19]. A similar approach
was used for the generation of the MT-4 mut cell lines. Four
mutations were introduced in the short hairpin that was expressed
from the transfer plasmid of the lentivral vector used. MT-4 cells
stably overexpressing LEDGF/p75 (MT-4 LEDGF/p75) or eGFP (MT-4
eGFP) were generated by transducing MT-4 cells with Combi_-
LEDGF_IRES_Puro vector or Combi_eGFP_IRES_Puro vector,
respectively. At 24 h prior to transduction, cells were seeded in a 96-
well plate at a density of 100,000 cells/well. After overnight
transduction at 37 8C in a 5% CO2 humidiﬁed atmosphere, the
medium was replaced. Five days posttransduction, selection with
puromycin (0.25 lg/ml) was initiated. At different time points during
selection, LEDGF/p75 expression was analyzed by Western blotting.
Virus strains. The HIV-1 molecular clone pNL4.3 [40] was obtained
through the AIDS Research and Reference Reagent Program,
Division of AIDS, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, contributed by Dr. Malcolm
Martin (Bethesda, Maryland, United States). To generate the A128T,
E170G, and A128T/E170G IN mutated viruses, site-directed muta-
genesis was performed using the Kirsch and Joly method [37]. The
presence of the expected mutations was conﬁrmed by DNA
sequencing of the entire IN coding region. Virus productions were
performed as described by De Rijck et al. [19].
Selection of resistance. The resistance selection of HIV-1 (NL4.3)
against overexpression of the C-terminal part of LEDGF/p75 was
initiated at a high MOI (25) in MT-4 eGFP-D325 cells. Simultaneously,
as a control, virus was also passaged in MT-4 eGFP-D325 D366A cells.
Every 3 to 4 d, the MT-4 cell culture was monitored for the
appearance of HIV-induced cytopathic effect (CPE). When CPE was
observed, the cell-free culture supernatant was used to infect fresh,
uninfected MT-4 eGFP-D325 or MT-4 eGFP-D325 D366A cells. To
increase selective pressure, the volume of supernatant transferred
was progressively decreased during the experiment from 1 ml to 50 ll
for 23 105 cells cultured in 2 ml of medium.
PCR ampliﬁcation and sequencing of the coding regions of IN.
Proviral DNA extraction of infected MT-4 eGFP-D325 cells was
performed using the QIAamp blood kit (Qiagen, http://www.qiagen.
com). PCR ampliﬁcation and sequencing of IN encoding sequences
were done as described previously [30]. Mutations present at least
25% of the global virus population can be detected as a mixture with
the WT amino acid by means of population sequencing.
HIV-1 infection. Infection of MT-4 and Jurkat cells was performed
with 13 106 cells in 1 ml of medium at an MOI of 0.1, 0.5, or 2.5 for 3
h. Different virus strains were normalized on p24 levels. After 3 h,
cells were washed twice with PBS and resuspended in 10 ml of MT-4
medium. HIV-1 replication was monitored by quantifying p24
antigen in the supernatant via ELISA (Alliance HIV-1 p24 ELISA
kit; Perkin Elmer, http://www.perkinelmer.com).
Replication kinetics. Either 500 or 5,000 TCID50 (50% tissue
culture infective doses) of each virus was used to infect 53 105 PHA-
stimulated PBLs (MOI¼0.001 or 0.01). TCID50 were determined using
the Spearman-Karber method [41]. Culture supernatants were
collected every day until day 7, and p24 antigen production was
monitored by ELISA (Perkin Elmer).
To study replication kinetics in MT-4 cells, inoculants of various
HIV-1 strains containing equal amounts of HIV-1 p24 antigen (10, 5,
and 2.5 pg/ml) were added to MT-4 cells (50,000 cells/ml). From 3 d
postinfection on, aliquots of cell-free supernatants were taken for
p24 level determination.
Real-time quantitative PCR analysis. One day prior to trans-
duction, 293T cells were seeded in 24-well plates at approximately 23
105 cells per well. Transductions with the VSV-G pseudotyped viruses
were carried out at an MOI of 10. Prior to infection, VSV-G virus
stocks were treated with RNase-free DNase I (0.2 U/ll) (Roche Applied
Sciences). Virus was added to the cells in the presence of DMEM–1%
FCS. After 3 h of incubation, medium was replaced by DMEM
containing 10% FCS. In each 24-well plate, noninfected 293T cells
were incubated in parallel. DNA extractions and quantiﬁcation of
late reverse transcripts, 2-LTR circles, and integrants were done as
described earlier [42,43]. Analysis of DNA extracted from lentivirus
tranduced cells was done as described earlier [19].
Laser scanning microscopy. HeLaP4, HeLaP4 eGFP-D325, and
HeLaP4 eGFP-D325 D366A cells were transfected with pmRFP-INs
and analyzed using a LSM510 unit (Zeiss, Zaventem, Belgium) as
described previously [16]. Overexpression of LEDGF/p75 in HeLa P4
cells was accomplished by cotransfection with peGFP-p75 [12].
FCCS analysis. FCCS measurements were performed on a
commercial LSM510/ConfoCor2 system (Carl Zeiss, Jena, Germany).
The 488-nm line of the Arþ- laser (AOTF 0.1%, approximately 25 lW)
was used to excite eGFP, and the 543-nm line of the HeNe laser
(AOTF 7%, approximately 70 lW) was used to excite mRFP1. The
excitation light was reﬂected by a dichroic mirror (HFT 488/543) and
focused through a type C-Apochromat 340/1.2W objective lens. The
ﬂuorescence emission light was split by a second dichroic mirror
(NFT 570) into two separate beam paths and passed through a 505- to
530-nm bandpass ﬁlter for eGFP ﬂuorescence and a 600- to 650-nm
bandpass ﬁlter for mRFP1 ﬂuorescence. Each confocal pinhole
diameter was set to 70 lm. After preparation of the cells in an
eight-well chambered coverglass (NUNC A/S, Roskilde, Denmark),
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laser scanning microscopy was used to search for cells suitable for
FCCS. The laser beam was focused at a selected spot, and an FCCS
measurement (103 20 s) was performed. Auto- and cross-correlation
curves were evaluated by a Levenberg-Marquardt nonlinear least-
squares ﬁtting to a two-component model, using the OriginPro 7.5
software (OriginLab, Northampton, Massachusetts, United States).
The relative cross-correlation is calculated from the following
formula: CCrel. ¼ Gcross(0)/Ggreen(0), with Gcross(0) and Ggreen(0) being
the amplitudes of the cross and green autocorrelation curves,
respectively [19].
Western blotting. Western blotting was performed as described
previously [16].
Production and puriﬁcation of recombinant proteins. Nontagged
LEDGF/p75 was produced from the plasmids pCPnat75 in Escherichia
coli BL21(DE3) and puriﬁed as described previously [12]. The
construction of pMBP-IBD, pMBP-D325, and pMBP-D325 D366A
and puriﬁcation of these fusion proteins from BL21 bacterial cells
were described previously [19]. HIV-1 IN enzymes were puriﬁed on a
nickel-nitrilotriacetic acid column (Qiagen), followed by a phospho-
cellulose cation exchange column (Whatman International, http://
www.whatman.com). The puriﬁed recombinant proteins were con-
centrated by ultraﬁltration using Centricon10 (Millipore, http://www.
millipore.com) or Vivaspin 15R (Vivascience, http://www.vivascience.
com). All IN protein concentrations were measured using the
Bradford assay (Bio-Rad, http://www.bio-rad.com). The puriﬁed
recombinant enzymes were analyzed on SDS-PAGE, supplemented
with 5 mM dithiothreitol (DTT) plus 10% glycerol, and frozen at
80 8C.
Substrate and target DNA used in the enzymatic IN assay. The
HPLC-puriﬁed deoxyoligonucleotides, INT1 (59-TGT GGA AAA TCT
CTA GCA GT) and INT2 (59-ACT GCT AGA GAT TTT CCA CA),
corresponding to the U5 end of the HIV-1 LTR, were purchased from
Amersham Biosciences (http://www.amersham.com). The oligonucleo-
tide INT1 was puriﬁed through a 20% denaturing polyacrylamide/
urea gel and was radioactively labeled at the 59-end using
polynucleotide T4 kinase and [c-32P]ATP (Amersham Biosciences).
The DNA substrate and target for IN reactions were made by
annealing INT1 and INT2. An equimolar mixture of the two
oligonucleotides in the presence of 100 mM NaCl was heated shortly
at 95 8C and allowed to cool slowly to room temperature.
The overall integration assay. The enzymatic integration reactions
were carried out as described previously [44–46] with minor
modiﬁcations [30]. Speciﬁc activities of different enzyme prepara-
tions were determined in this assay. The extent of overall integration
was based on measuring the amounts of strand transfer products of
the mutant INs in comparison with WT IN. These data were
determined using the OptiQuant Acquisition and Analysis software
(Perkin Elmer Corporate).
His6 Tag IN Pull-down Assay. His6 tag IN pull-down assay was
adapted from Maertens et al. [12], with minor modiﬁcations. Binding
of IN to LEDGF/p75, IBD-MBP, and D325-MBP was assayed in 25 mM
Tris-HCl (pH 7.4), 0.1% Nonidet P-40, and 20 mM imidazole
containing 150 mM NaCl, in the presence of 1 mM MgCl2 (binding
buffer). Then, 6 lg of recombinant C-terminal His6-tagged IN was
incubated with 40 ll of Ni-NTA-agarose for 10 min at 4 8C. Next, 6 lg
of LEDGF/p75 in 200 ll of binding buffer supplemented with 4 lg of
BSA was added to the mixture. Following 4-h incubation at 4 8C, the
agarose beads were recovered by centrifugation for 2 min at 13,000
rpm at 4 8C and washed several times with 300 ll of binding buffer.
Bound proteins were eluted in 20 ll of binding buffer supplemented
with 200 mM imidazole and 1% SDS and analyzed by 11% SDS-PAGE
followed by staining with Coomassie Blue R-250 [12].
AlphaScreen. To conﬁrm the loss of interaction of the mutant INs
to the D325 fragment, AlphaScreen technology (Perkin Elmer) was
performed. In a 384-well plate, 0, 30, 100, or 300 nM of IN was added
to 0, 10, 30, or 100 nM MBP-D325 at room temperature in assay buffer
(25 mM Tris/HCl [pH 7.3], 150 mM NaCl, 1 mM MgCl2, 0.01% Tween-
20, 0.1% BSA). The mixture was incubated for 90 min at room
temperature. For subsequent binding of the proteins to the beads, Ni-
chelate–coated acceptor beads and streptavidin-coated donor beads
premixed with biotinylated anti-MBP antibody (Vector Laboratories,
http://www.vectorlabs.com) were added to a ﬁnal concentration of 20
lg/ml. All dilutions were done in assay buffer and, if necessary, the
ﬁnal volume of the reaction was adjusted to 25 ll. In order to bind the
anti-MBP antibody to the streptavidin-coated donor beads, the
antibody was dialyzed overnight against assay buffer without BSA,
added to the beads in a ﬁnal concentration of 50 nM, and incubated
for 1 h at room temperature. After addition of the beads to the
binding assay, light exposure was omitted and the incubation was
carried out for an additional 60 min before analyzing the interaction
in the EnVision plate reader (Perkin Elmer).
Biomolecular modeling. In order to investigate the structural
inﬂuences caused by the mutations on the LEDGF/p75 HIV-1 IN
interface, a biomolecular modeling approach was used. Structural
data of the binding of these two proteins are limited to the crystal
structure 2B4J of the HIV-CCD dimer with two IBD fragments [28].
Unresolved loops in the crystal structure were ﬁrst completed using
the B chain of the CCD 1BIS structure [47]. Four different complexes
were generated: the WT, the single mutated, and the double mutant
structure. Both CCD IN chains of the dimer were mutated. After
mutation of the residues and reﬁnement of the mutated residue, a
sphere with a radius of 9 A˚ was subsequently minimized using a
CHARMM-based force ﬁeld [48]. Crystallographic water molecules
were incorporated, and an additional water box was used during the
energy minimization. In order to analyze the inﬂuence of the
mutations, the nonbonded interaction energy of the interface and
the contribution of the electrostatic energy, Van Der Waals energy,
and hydrogen bonding energy were computed for the LEDGF/p75 IN
interface and the residues of the interface. Crystallographic water
molecules bound in the interface were taken in account for these
computations. The computations were performed using MOE (The
Molecular Operating Environment, Chemical Computing Group,
1255 University Street, Suite 1600; Montreal, Quebec, Canada H3B
3X3) (modeling) and Brugel [49] (analysis).
Supporting Information
Figure S1. Effect of eGFP-D325 Overexpression on HIV-1 Replication
(A) Schematic representation of HIV-1 integration in MT-4 and MT-4
eGFP-D325 cells. In MT-4 cells, association with LEDGF/p75 tethers
IN to the chromatin, facilitating the integration of the viral cDNA in
the host genome. When eGFP-D325 is overexpressed, eGFP-D325
competes with endogenous LEDGF/p75 for binding to IN and thereby
inhibits viral integration. Note that the concentrations of LEDGF/p75
and eGFP-D325 proteins shown are arbitrary.
(B) HIV-1 (NL4.3) replication in MT-4 eGFP-D325 D366A cells (ﬁlled
diamonds) and MT-4 eGFP-D325 cells (open diamonds). MT-4 cells
were infected at an MOI of 0.1, and viral replication was followed by
measurement of p24 antigen in the supernatant.
Found at doi:10.1371/journal.ppat.0030047.sg001 (4.1 MB TIF).
Figure S2. Effect of Resistance Mutations on Viral DNA Formation
during Replication
(A–C) 293T cells were infected with VSV-G pseudotyped viral clones:
WT NL4.3 (diamonds), NL4.3 A128T (boxes), NL4.3 E170G (triangles),
or NL4.3 A128T/E170G (crosses). DNA was extracted at different time
points postinfection, and the amounts of (A) total viral DNA, (B) 2-
LTR circles, and (C) proviruses were determined by quantitative PCR.
(D–F) 293T eGFP-D325 and 293T eGFP-D325 D366A cells were
infected with VSV-G pseudotyped viral clones: WT NL4.3 (diamonds)
or NL4.3 A128T/E170G (crosses). DNA was extracted at different time
points postinfection, and the amounts of (D) total viral DNA and (E)
2-LTR circles were determined by quantitative PCR. To quantify
integrated DNA (F), the total viral DNA was measured 144 h
postinfection (i.e., after six cell divisions). Quantiﬁcations were
performed in duplicate. Averages 6 SD are shown.
Found at doi:10.1371/journal.ppat.0030047.sg002 (4.1 MB TIF).
Figure S3. Effect of Resistance Mutations on Nuclear Localization of
mRFP-INs
HeLaP4, HeLaP4 eGFP-D325, and HeLaP4 eGFP-D325 D366A were
transfected with different mRFP-INss, 24 h before laser scanning
microscopy.
(A) mRFP-INs expression in HeLaP4 cells.
(B) mRFP-INs expression in HeLaP4 eGFP-D325 and HeLa P4 eGFP-
D325 D366A cells.
(C) mRFP-INs expression upon overexpression of eGFP-LEDGF/p75
in HeLaP4 cells.
Found at doi:10.1371/journal.ppat.0030047.sg003 (6.4 MB TIF).
Figure S4. Visualization of the IN-IBD Binding Site and Inﬂuence of
the IN A128T and E170G Mutations Using Biomolecular Modeling
Models were drawn with PYMOL (W. L. DeLano, http://www.pymol.
org). IN chains A and B are colored blue and green, respectively,
while the IBD subunits are violet. Selected residues are shown as
sticks, and hydrogen bonds are indicated by dotted lines.
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(A) Binding of the two WT catalytic core domains with the IBD (PDB
code 2B4J). A128 is part of the a3 helix in the IN-CCD, which forms a
hydrophobic patch that accommodates the side chains of the LEDGF
residues I365, F406, and V408 [28]. E170 is part of the so-called a4/5
connector, a six-residue connector linking helices a4 and a5 of the
second IN chain (residues 166 through 171).
(B) Representation of the model showing the effect of mutating A128 to
T128 and E170 to G170. For A128T, the bulky side chain of threonine
causes sterical hindrance, thereby forcing the I368 residue of the IBD to
adapt a different conformation. This occurs without a drastic inﬂuence
on the conformation of residues in the LEDGF/p75 IN binding
interface. The E170Gmutation has a more drastic effect. This mutation
results in a different conformation of the loop disrupting two
interactions. First, the double hydrogen bond between the hydrogens
of the loop backbone at residues E170 and H171 and D366, a critical
interacting residue on LEDGF/p75, is broken. Second, the electrostatic
interaction of E170 (IN) with K364 (LEDGF/p75) is abolished.
Found at doi:10.1371/journal.ppat.0030047.sg004 (6.5 MB TIF).
Figure S5. Reduced Replication Kinetics of NL4.3 A128T/E170G Are
due to Reduced Afﬁnity for LEDGF/p75
(A) Western blot analysis of LEDGF/p75 expression levels in MT-4
cells (lane 1) and MT-4 cells stably overexpressing LEDGF/p75 (lane
2). As a control, MT-4 cells expressing eGFP were made (MT-4 eGFP)
(lane 3). Equal loading was controlled by a-tubulin detection.
(B) MT-4 LEDGF/p75 cells and MT-4 eGFP cells were infected with 10
pg/ml p24 antigen: WT NL4.3 (diamonds) or NL4.3 A128T/E170G
(crosses). The replication kinetics for the viruses was determined by
measuring viral p24 antigen levels in the supernatant. Experiments
were performed in duplicate. Averages 6 SD are shown.
Found at doi:10.1371/journal.ppat.0030047.sg005 (1.3 MB TIF).
Accession Numbers
The Genbank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for the proteins discussed in this paper are LEDGF/p75
(NM_033222) and HIV-1 NL4–3 IN (U26942; base pairs 3608 through
4471).
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